

## **Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases**

**Brisbane, Australia. 2 November 2007:** Progen Pharmaceuticals Limited (ASX:PGL; NASDAQ:PGLA) today announced that Dr James Garner, Progen's Vice President of Clinical and Medical Affairs will present a poster entitled "The Interactive Effect of Prognostic Factors and PI-88 Use on the Delay of HCC Recurrence Following Curative Partial Hepatic Resection" at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA<sup>1</sup> on Saturday, 3 November 2007.

The poster presentation will be made available on Progen's website [www.progen-pharma.com](http://www.progen-pharma.com) from approximately 9am (Brisbane time) Saturday 3 November 2007.

<sup>1</sup>Each year, the American Association for the Study of Liver Diseases brings together over 6,000 hepatologists and hepatology health professionals from around the world for its annual meeting to meet and exchange the latest liver disease research, and discuss treatment outcomes.

**About PI-88:** PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes – angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) – critical to the growth and progression of cancer. In a phase 2 trial in post-resection liver cancer, 160mg of PI-88 demonstrated a 25% improvement in the primary endpoint of disease-free rate at 48 weeks and 78% improvement in secondary endpoint of disease-free survival. These results, combined with positive feedback from the FDA, provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

**About Progen:** Progen Pharmaceuticals Limited is an Australia-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.

### **Progen Information:**

Linton Burns  
Progen Pharmaceuticals Limited  
T: +61 7 3842 3333  
E: [lintonb@progen-pharma.com](mailto:lintonb@progen-pharma.com)

### **Media and Investor Relations Australia:**

Rebecca Wilson  
Buchan Consulting  
T: +61 2 9237 2800  
M: +61 417 382 391  
E: [rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

Phillipa Harris  
Buchan Consulting  
T: +61 2 9237 2800  
M: +61 408 465 800  
E: [pharris@bcg.com.au](mailto:pharris@bcg.com.au)

### **Media Relations USA:**

Robert D. Stanislaro  
Financial Dynamics  
T: 212-850-5657  
E: [robert.stanislaro@fd.com](mailto:robert.stanislaro@fd.com)

### **Investor Relations USA:**

Evan Smith  
Financial Dynamics  
T: 212-850-5606  
E: [evan.smith@fd.com](mailto:evan.smith@fd.com)

